Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asasantin Retard for Raynaud's Phenomenon and Systemic Sclerosis (Pilot)
2009-013468-37Phase 2Completed
- Sponsor
- Royal National Hospital for Rheumatic Diseases
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dipyridamole + aspirin in Raynaud disease and systemic sclerosis (SSc), sponsored by Royal National Hospital for Rheumatic Diseases. Primary endpoint: Raynaud's Condition Score change. Started Mar 2010; status: completed.
02
Drugs
dipyridamole + aspirin
03
Conditions
Raynaud diseasesystemic sclerosis (SSc)
Beyond the preview
Go deeper on 2009-013468-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013468-37.